Cancer Photodynamic Therapy Comprehensive Study by Type (Drugs, Devices), Application (Actinic Keratosis (AK), Cancer, Acne, Psoriasis, Others), End-users (Hospitals, Cancer Treatment Centers, Cosmetic and Dermatology Clinics, Others), Side Effects (Cough, Trouble Swallowing, Stomach Pain, Painful Breathing, Shortness of Breath, Skin Problems) Players and Region - Global Market Outlook to 2028

Cancer Photodynamic Therapy Market by XX Submarkets | Forecast Years 2023-2028  

  • Summary
  • Market Segments
  • Table of Content
  • List of Table & Figures
  • Players Profiled
Global Cancer Photodynamic Therapy Market Overview:
Photodynamic remedy makes use of a drug that is activated with the aid of light, known as a photosensitizer or photosensitizing agent, to kill most cancers cells. The mild can come from a laser or different source, such as LEDs. Photodynamic remedy is additionally known as PDT. Depending on the phase of the physique being treated, the photosensitizing agent is both put into the bloodstream thru a vein and put on the skin. Over a positive quantity of time the drug is absorbed through the most cancers cells. Then mild is utilized to the location to be treated. The mild motives the drug to react and shape a unique variety of oxygen molecule that kills the cells. PDT may additionally assist through destroying the blood vessels that feed the most cancers cells and by using alerting the immune device to assault the cancer.

AttributesDetails
Study Period2018-2028
Base Year2022
Forecast Period2023-2028
Historical Period2018-2022
UnitValue (USD Million)
Customization ScopeAvail customization with purchase of this report. Add or modify country, region & or narrow down segments in the final scope subject to feasibility


Influencing Trend:
Developing Improved Formulations of Porphyrin-Derivative (PD) Compounds

Market Growth Drivers:
Increasing Prevalence of Skin Cancer and Advancements in Device Technologies

Challenges:
Companies Are Increasing Their Production Capabilities to Improve the Efficacy of Novel Delivery Systems in Photodynamic Therapy

Restraints:
High Cost of Photodynamic Therapy Devices and Stringent Regulatory Policies and Risk Associated With the Photodynamic Therapy

Opportunities:
Rising Prevalence of Skin Cancer Is Expected To Fuel the Growth of the Photodynamic Therapy Market

Competitive Landscape:
The global market is highly competitive and consists of a limited number of providers who compete with each other. The intense competition, changing consumer spending patterns, demographic trends, and frequent changes in consumer preferences pose significant opportunities for market growth.
Some of the key players profiled in the report are Theralase Technologies Inc. (Canada), Biofrontera AG (Germany), Hologic Inc. (United States), Bausch Health (Canada), Quest PharmaTech Inc. (Canada), LUMIBIRD (France), Galderma Laboratories L.P. (Switzerland), Sun Pharmaceutical Industries Limited (India), Allergan plc (Ireland) and Modulight Inc. (Finland). Additionally, following companies can also be profiled that are part of our coverage like SUS Advancing Technology Co. Ltd (China), Lumenis Ltd. (Israel), PhotoMedex Inc. (United States), Dusa Pharmaceuticals (United States) and Soligenix Inc. (United States). Analyst at AMA Research see United States Players to retain maximum share of Global Cancer Photodynamic Therapy market by 2028. Considering Market by End-users, the sub-segment i.e. Hospitals will boost the Cancer Photodynamic Therapy market. Considering Market by Side Effects, the sub-segment i.e. Cough will boost the Cancer Photodynamic Therapy market.

Latest Market Insights:
In 2019, Biofrontera AG, a German-based biopharmaceutical player, launched its Phase III scientific trial assessing the protection and effectiveness of photodynamic remedy with Ameluz and the BF-RhodoLED lamp for the use in the analysis of actinic keratoses (AK).



What Can be Explored with the Cancer Photodynamic Therapy Market Study
 Gain Market Understanding
 Identify Growth Opportunities
 Analyze and Measure the Global Cancer Photodynamic Therapy Market by Identifying Investment across various Industry Verticals
 Understand the Trends that will drive Future Changes in Cancer Photodynamic Therapy
 Understand the Competitive Scenario
- Track Right Markets
- Identify the Right Verticals

Research Methodology:
The top-down and bottom-up approaches are used to estimate and validate the size of the Global Cancer Photodynamic Therapy market.
In order to reach an exhaustive list of functional and relevant players various industry classification standards are closely followed such as NAICS, ICB, SIC to penetrate deep in important geographies by players and a thorough validation test is conducted to reach most relevant players for survey in Cancer Photodynamic Therapy market.
In order to make priority list sorting is done based on revenue generated based on latest reporting with the help of paid databases such as Factiva, Bloomberg etc.
Finally the questionnaire is set and specifically designed to address all the necessities for primary data collection after getting prior appointment by targeting key target audience that includes Cancer Photodynamic Therapy Provider, Venture Capitalists and Private Equity Firms, Government Bodies, Corporate Entities, Government and Private Research Organizations and Others.
This helps us to gather the data related to players revenue, operating cycle and expense, profit along with product or service growth etc.
Almost 70-80% of data is collected through primary medium and further validation is done through various secondary sources that includes Regulators, World Bank, Association, Company Website, SEC filings, OTC BB, USPTO, EPO, Annual reports, press releases etc.

Report Objectives / Segmentation Covered

By Type
  • Drugs
  • Devices
By Application
  • Actinic Keratosis (AK)
  • Cancer
  • Acne
  • Psoriasis
  • Others
By End-users
  • Hospitals
  • Cancer Treatment Centers
  • Cosmetic and Dermatology Clinics
  • Others

By Side Effects
  • Cough
  • Trouble Swallowing
  • Stomach Pain
  • Painful Breathing
  • Shortness of Breath
  • Skin Problems

By Regions
  • South America
    • Brazil
    • Argentina
    • Rest of South America
  • Asia Pacific
    • China
    • Japan
    • India
    • South Korea
    • Australia
    • Rest of Asia-Pacific
  • Europe
    • Germany
    • France
    • Italy
    • United Kingdom
    • Netherlands
    • Rest of Europe
  • MEA
    • Middle East
    • Africa
  • North America
    • United States
    • Canada
    • Mexico
  • 1. Market Overview
    • 1.1. Introduction
    • 1.2. Scope/Objective of the Study
      • 1.2.1. Research Objective
  • 2. Executive Summary
    • 2.1. Introduction
  • 3. Market Dynamics
    • 3.1. Introduction
    • 3.2. Market Drivers
      • 3.2.1. Increasing Prevalence of Skin Cancer
      • 3.2.2. Advancements in Device Technologies
    • 3.3. Market Challenges
      • 3.3.1. Companies Are Increasing Their Production Capabilities to Improve the Efficacy of Novel Delivery Systems in Photodynamic Therapy
    • 3.4. Market Trends
      • 3.4.1. Developing Improved Formulations of Porphyrin-Derivative (PD) Compounds
  • 4. Market Factor Analysis
    • 4.1. Porters Five Forces
    • 4.2. Supply/Value Chain
    • 4.3. PESTEL analysis
    • 4.4. Market Entropy
    • 4.5. Patent/Trademark Analysis
  • 5. Global Cancer Photodynamic Therapy, by Type, Application, End-users, Side Effects and Region (value) (2017-2022)
    • 5.1. Introduction
    • 5.2. Global Cancer Photodynamic Therapy (Value)
      • 5.2.1. Global Cancer Photodynamic Therapy by: Type (Value)
        • 5.2.1.1. Drugs
        • 5.2.1.2. Devices
      • 5.2.2. Global Cancer Photodynamic Therapy by: Application (Value)
        • 5.2.2.1. Actinic Keratosis (AK)
        • 5.2.2.2. Cancer
        • 5.2.2.3. Acne
        • 5.2.2.4. Psoriasis
        • 5.2.2.5. Others
      • 5.2.3. Global Cancer Photodynamic Therapy by: End-users (Value)
        • 5.2.3.1. Hospitals
        • 5.2.3.2. Cancer Treatment Centers
        • 5.2.3.3. Cosmetic and Dermatology Clinics
        • 5.2.3.4. Others
      • 5.2.4. Global Cancer Photodynamic Therapy by: Side Effects (Value)
        • 5.2.4.1. Cough
        • 5.2.4.2. Trouble Swallowing
        • 5.2.4.3. Stomach Pain
        • 5.2.4.4. Painful Breathing
        • 5.2.4.5. Shortness of Breath
        • 5.2.4.6. Skin Problems
      • 5.2.5. Global Cancer Photodynamic Therapy Region
        • 5.2.5.1. South America
          • 5.2.5.1.1. Brazil
          • 5.2.5.1.2. Argentina
          • 5.2.5.1.3. Rest of South America
        • 5.2.5.2. Asia Pacific
          • 5.2.5.2.1. China
          • 5.2.5.2.2. Japan
          • 5.2.5.2.3. India
          • 5.2.5.2.4. South Korea
          • 5.2.5.2.5. Australia
          • 5.2.5.2.6. Rest of Asia-Pacific
        • 5.2.5.3. Europe
          • 5.2.5.3.1. Germany
          • 5.2.5.3.2. France
          • 5.2.5.3.3. Italy
          • 5.2.5.3.4. United Kingdom
          • 5.2.5.3.5. Netherlands
          • 5.2.5.3.6. Rest of Europe
        • 5.2.5.4. MEA
          • 5.2.5.4.1. Middle East
          • 5.2.5.4.2. Africa
        • 5.2.5.5. North America
          • 5.2.5.5.1. United States
          • 5.2.5.5.2. Canada
          • 5.2.5.5.3. Mexico
  • 6. Cancer Photodynamic Therapy: Manufacturers/Players Analysis
    • 6.1. Competitive Landscape
      • 6.1.1. Market Share Analysis
        • 6.1.1.1. Top 3
        • 6.1.1.2. Top 5
    • 6.2. Peer Group Analysis (2022)
    • 6.3. BCG Matrix
    • 6.4. Company Profile
      • 6.4.1. Theralase Technologies Inc. (Canada)
        • 6.4.1.1. Business Overview
        • 6.4.1.2. Products/Services Offerings
        • 6.4.1.3. Financial Analysis
        • 6.4.1.4. SWOT Analysis
      • 6.4.2. Biofrontera AG (Germany)
        • 6.4.2.1. Business Overview
        • 6.4.2.2. Products/Services Offerings
        • 6.4.2.3. Financial Analysis
        • 6.4.2.4. SWOT Analysis
      • 6.4.3. Hologic Inc. (United States)
        • 6.4.3.1. Business Overview
        • 6.4.3.2. Products/Services Offerings
        • 6.4.3.3. Financial Analysis
        • 6.4.3.4. SWOT Analysis
      • 6.4.4. Bausch Health (Canada)
        • 6.4.4.1. Business Overview
        • 6.4.4.2. Products/Services Offerings
        • 6.4.4.3. Financial Analysis
        • 6.4.4.4. SWOT Analysis
      • 6.4.5. Quest PharmaTech Inc. (Canada)
        • 6.4.5.1. Business Overview
        • 6.4.5.2. Products/Services Offerings
        • 6.4.5.3. Financial Analysis
        • 6.4.5.4. SWOT Analysis
      • 6.4.6. LUMIBIRD (France)
        • 6.4.6.1. Business Overview
        • 6.4.6.2. Products/Services Offerings
        • 6.4.6.3. Financial Analysis
        • 6.4.6.4. SWOT Analysis
      • 6.4.7. Galderma Laboratories L.P. (Switzerland)
        • 6.4.7.1. Business Overview
        • 6.4.7.2. Products/Services Offerings
        • 6.4.7.3. Financial Analysis
        • 6.4.7.4. SWOT Analysis
      • 6.4.8. Sun Pharmaceutical Industries Limited (India)
        • 6.4.8.1. Business Overview
        • 6.4.8.2. Products/Services Offerings
        • 6.4.8.3. Financial Analysis
        • 6.4.8.4. SWOT Analysis
      • 6.4.9. Allergan plc (Ireland)
        • 6.4.9.1. Business Overview
        • 6.4.9.2. Products/Services Offerings
        • 6.4.9.3. Financial Analysis
        • 6.4.9.4. SWOT Analysis
      • 6.4.10. Modulight Inc. (Finland)
        • 6.4.10.1. Business Overview
        • 6.4.10.2. Products/Services Offerings
        • 6.4.10.3. Financial Analysis
        • 6.4.10.4. SWOT Analysis
  • 7. Global Cancer Photodynamic Therapy Sale, by Type, Application, End-users, Side Effects and Region (value) (2023-2028)
    • 7.1. Introduction
    • 7.2. Global Cancer Photodynamic Therapy (Value)
      • 7.2.1. Global Cancer Photodynamic Therapy by: Type (Value)
        • 7.2.1.1. Drugs
        • 7.2.1.2. Devices
      • 7.2.2. Global Cancer Photodynamic Therapy by: Application (Value)
        • 7.2.2.1. Actinic Keratosis (AK)
        • 7.2.2.2. Cancer
        • 7.2.2.3. Acne
        • 7.2.2.4. Psoriasis
        • 7.2.2.5. Others
      • 7.2.3. Global Cancer Photodynamic Therapy by: End-users (Value)
        • 7.2.3.1. Hospitals
        • 7.2.3.2. Cancer Treatment Centers
        • 7.2.3.3. Cosmetic and Dermatology Clinics
        • 7.2.3.4. Others
      • 7.2.4. Global Cancer Photodynamic Therapy by: Side Effects (Value)
        • 7.2.4.1. Cough
        • 7.2.4.2. Trouble Swallowing
        • 7.2.4.3. Stomach Pain
        • 7.2.4.4. Painful Breathing
        • 7.2.4.5. Shortness of Breath
        • 7.2.4.6. Skin Problems
      • 7.2.5. Global Cancer Photodynamic Therapy Region
        • 7.2.5.1. South America
          • 7.2.5.1.1. Brazil
          • 7.2.5.1.2. Argentina
          • 7.2.5.1.3. Rest of South America
        • 7.2.5.2. Asia Pacific
          • 7.2.5.2.1. China
          • 7.2.5.2.2. Japan
          • 7.2.5.2.3. India
          • 7.2.5.2.4. South Korea
          • 7.2.5.2.5. Australia
          • 7.2.5.2.6. Rest of Asia-Pacific
        • 7.2.5.3. Europe
          • 7.2.5.3.1. Germany
          • 7.2.5.3.2. France
          • 7.2.5.3.3. Italy
          • 7.2.5.3.4. United Kingdom
          • 7.2.5.3.5. Netherlands
          • 7.2.5.3.6. Rest of Europe
        • 7.2.5.4. MEA
          • 7.2.5.4.1. Middle East
          • 7.2.5.4.2. Africa
        • 7.2.5.5. North America
          • 7.2.5.5.1. United States
          • 7.2.5.5.2. Canada
          • 7.2.5.5.3. Mexico
  • 8. Appendix
    • 8.1. Acronyms
  • 9. Methodology and Data Source
    • 9.1. Methodology/Research Approach
      • 9.1.1. Research Programs/Design
      • 9.1.2. Market Size Estimation
      • 9.1.3. Market Breakdown and Data Triangulation
    • 9.2. Data Source
      • 9.2.1. Secondary Sources
      • 9.2.2. Primary Sources
    • 9.3. Disclaimer
List of Tables
  • Table 1. Cancer Photodynamic Therapy: by Type(USD Million)
  • Table 2. Cancer Photodynamic Therapy Drugs , by Region USD Million (2017-2022)
  • Table 3. Cancer Photodynamic Therapy Devices , by Region USD Million (2017-2022)
  • Table 4. Cancer Photodynamic Therapy: by Application(USD Million)
  • Table 5. Cancer Photodynamic Therapy Actinic Keratosis (AK) , by Region USD Million (2017-2022)
  • Table 6. Cancer Photodynamic Therapy Cancer , by Region USD Million (2017-2022)
  • Table 7. Cancer Photodynamic Therapy Acne , by Region USD Million (2017-2022)
  • Table 8. Cancer Photodynamic Therapy Psoriasis , by Region USD Million (2017-2022)
  • Table 9. Cancer Photodynamic Therapy Others , by Region USD Million (2017-2022)
  • Table 10. Cancer Photodynamic Therapy: by End-users(USD Million)
  • Table 11. Cancer Photodynamic Therapy Hospitals , by Region USD Million (2017-2022)
  • Table 12. Cancer Photodynamic Therapy Cancer Treatment Centers , by Region USD Million (2017-2022)
  • Table 13. Cancer Photodynamic Therapy Cosmetic and Dermatology Clinics , by Region USD Million (2017-2022)
  • Table 14. Cancer Photodynamic Therapy Others , by Region USD Million (2017-2022)
  • Table 15. Cancer Photodynamic Therapy: by Side Effects(USD Million)
  • Table 16. Cancer Photodynamic Therapy Cough , by Region USD Million (2017-2022)
  • Table 17. Cancer Photodynamic Therapy Trouble Swallowing , by Region USD Million (2017-2022)
  • Table 18. Cancer Photodynamic Therapy Stomach Pain , by Region USD Million (2017-2022)
  • Table 19. Cancer Photodynamic Therapy Painful Breathing , by Region USD Million (2017-2022)
  • Table 20. Cancer Photodynamic Therapy Shortness of Breath , by Region USD Million (2017-2022)
  • Table 21. Cancer Photodynamic Therapy Skin Problems , by Region USD Million (2017-2022)
  • Table 22. South America Cancer Photodynamic Therapy, by Country USD Million (2017-2022)
  • Table 23. South America Cancer Photodynamic Therapy, by Type USD Million (2017-2022)
  • Table 24. South America Cancer Photodynamic Therapy, by Application USD Million (2017-2022)
  • Table 25. South America Cancer Photodynamic Therapy, by End-users USD Million (2017-2022)
  • Table 26. South America Cancer Photodynamic Therapy, by Side Effects USD Million (2017-2022)
  • Table 27. Brazil Cancer Photodynamic Therapy, by Type USD Million (2017-2022)
  • Table 28. Brazil Cancer Photodynamic Therapy, by Application USD Million (2017-2022)
  • Table 29. Brazil Cancer Photodynamic Therapy, by End-users USD Million (2017-2022)
  • Table 30. Brazil Cancer Photodynamic Therapy, by Side Effects USD Million (2017-2022)
  • Table 31. Argentina Cancer Photodynamic Therapy, by Type USD Million (2017-2022)
  • Table 32. Argentina Cancer Photodynamic Therapy, by Application USD Million (2017-2022)
  • Table 33. Argentina Cancer Photodynamic Therapy, by End-users USD Million (2017-2022)
  • Table 34. Argentina Cancer Photodynamic Therapy, by Side Effects USD Million (2017-2022)
  • Table 35. Rest of South America Cancer Photodynamic Therapy, by Type USD Million (2017-2022)
  • Table 36. Rest of South America Cancer Photodynamic Therapy, by Application USD Million (2017-2022)
  • Table 37. Rest of South America Cancer Photodynamic Therapy, by End-users USD Million (2017-2022)
  • Table 38. Rest of South America Cancer Photodynamic Therapy, by Side Effects USD Million (2017-2022)
  • Table 39. Asia Pacific Cancer Photodynamic Therapy, by Country USD Million (2017-2022)
  • Table 40. Asia Pacific Cancer Photodynamic Therapy, by Type USD Million (2017-2022)
  • Table 41. Asia Pacific Cancer Photodynamic Therapy, by Application USD Million (2017-2022)
  • Table 42. Asia Pacific Cancer Photodynamic Therapy, by End-users USD Million (2017-2022)
  • Table 43. Asia Pacific Cancer Photodynamic Therapy, by Side Effects USD Million (2017-2022)
  • Table 44. China Cancer Photodynamic Therapy, by Type USD Million (2017-2022)
  • Table 45. China Cancer Photodynamic Therapy, by Application USD Million (2017-2022)
  • Table 46. China Cancer Photodynamic Therapy, by End-users USD Million (2017-2022)
  • Table 47. China Cancer Photodynamic Therapy, by Side Effects USD Million (2017-2022)
  • Table 48. Japan Cancer Photodynamic Therapy, by Type USD Million (2017-2022)
  • Table 49. Japan Cancer Photodynamic Therapy, by Application USD Million (2017-2022)
  • Table 50. Japan Cancer Photodynamic Therapy, by End-users USD Million (2017-2022)
  • Table 51. Japan Cancer Photodynamic Therapy, by Side Effects USD Million (2017-2022)
  • Table 52. India Cancer Photodynamic Therapy, by Type USD Million (2017-2022)
  • Table 53. India Cancer Photodynamic Therapy, by Application USD Million (2017-2022)
  • Table 54. India Cancer Photodynamic Therapy, by End-users USD Million (2017-2022)
  • Table 55. India Cancer Photodynamic Therapy, by Side Effects USD Million (2017-2022)
  • Table 56. South Korea Cancer Photodynamic Therapy, by Type USD Million (2017-2022)
  • Table 57. South Korea Cancer Photodynamic Therapy, by Application USD Million (2017-2022)
  • Table 58. South Korea Cancer Photodynamic Therapy, by End-users USD Million (2017-2022)
  • Table 59. South Korea Cancer Photodynamic Therapy, by Side Effects USD Million (2017-2022)
  • Table 60. Australia Cancer Photodynamic Therapy, by Type USD Million (2017-2022)
  • Table 61. Australia Cancer Photodynamic Therapy, by Application USD Million (2017-2022)
  • Table 62. Australia Cancer Photodynamic Therapy, by End-users USD Million (2017-2022)
  • Table 63. Australia Cancer Photodynamic Therapy, by Side Effects USD Million (2017-2022)
  • Table 64. Rest of Asia-Pacific Cancer Photodynamic Therapy, by Type USD Million (2017-2022)
  • Table 65. Rest of Asia-Pacific Cancer Photodynamic Therapy, by Application USD Million (2017-2022)
  • Table 66. Rest of Asia-Pacific Cancer Photodynamic Therapy, by End-users USD Million (2017-2022)
  • Table 67. Rest of Asia-Pacific Cancer Photodynamic Therapy, by Side Effects USD Million (2017-2022)
  • Table 68. Europe Cancer Photodynamic Therapy, by Country USD Million (2017-2022)
  • Table 69. Europe Cancer Photodynamic Therapy, by Type USD Million (2017-2022)
  • Table 70. Europe Cancer Photodynamic Therapy, by Application USD Million (2017-2022)
  • Table 71. Europe Cancer Photodynamic Therapy, by End-users USD Million (2017-2022)
  • Table 72. Europe Cancer Photodynamic Therapy, by Side Effects USD Million (2017-2022)
  • Table 73. Germany Cancer Photodynamic Therapy, by Type USD Million (2017-2022)
  • Table 74. Germany Cancer Photodynamic Therapy, by Application USD Million (2017-2022)
  • Table 75. Germany Cancer Photodynamic Therapy, by End-users USD Million (2017-2022)
  • Table 76. Germany Cancer Photodynamic Therapy, by Side Effects USD Million (2017-2022)
  • Table 77. France Cancer Photodynamic Therapy, by Type USD Million (2017-2022)
  • Table 78. France Cancer Photodynamic Therapy, by Application USD Million (2017-2022)
  • Table 79. France Cancer Photodynamic Therapy, by End-users USD Million (2017-2022)
  • Table 80. France Cancer Photodynamic Therapy, by Side Effects USD Million (2017-2022)
  • Table 81. Italy Cancer Photodynamic Therapy, by Type USD Million (2017-2022)
  • Table 82. Italy Cancer Photodynamic Therapy, by Application USD Million (2017-2022)
  • Table 83. Italy Cancer Photodynamic Therapy, by End-users USD Million (2017-2022)
  • Table 84. Italy Cancer Photodynamic Therapy, by Side Effects USD Million (2017-2022)
  • Table 85. United Kingdom Cancer Photodynamic Therapy, by Type USD Million (2017-2022)
  • Table 86. United Kingdom Cancer Photodynamic Therapy, by Application USD Million (2017-2022)
  • Table 87. United Kingdom Cancer Photodynamic Therapy, by End-users USD Million (2017-2022)
  • Table 88. United Kingdom Cancer Photodynamic Therapy, by Side Effects USD Million (2017-2022)
  • Table 89. Netherlands Cancer Photodynamic Therapy, by Type USD Million (2017-2022)
  • Table 90. Netherlands Cancer Photodynamic Therapy, by Application USD Million (2017-2022)
  • Table 91. Netherlands Cancer Photodynamic Therapy, by End-users USD Million (2017-2022)
  • Table 92. Netherlands Cancer Photodynamic Therapy, by Side Effects USD Million (2017-2022)
  • Table 93. Rest of Europe Cancer Photodynamic Therapy, by Type USD Million (2017-2022)
  • Table 94. Rest of Europe Cancer Photodynamic Therapy, by Application USD Million (2017-2022)
  • Table 95. Rest of Europe Cancer Photodynamic Therapy, by End-users USD Million (2017-2022)
  • Table 96. Rest of Europe Cancer Photodynamic Therapy, by Side Effects USD Million (2017-2022)
  • Table 97. MEA Cancer Photodynamic Therapy, by Country USD Million (2017-2022)
  • Table 98. MEA Cancer Photodynamic Therapy, by Type USD Million (2017-2022)
  • Table 99. MEA Cancer Photodynamic Therapy, by Application USD Million (2017-2022)
  • Table 100. MEA Cancer Photodynamic Therapy, by End-users USD Million (2017-2022)
  • Table 101. MEA Cancer Photodynamic Therapy, by Side Effects USD Million (2017-2022)
  • Table 102. Middle East Cancer Photodynamic Therapy, by Type USD Million (2017-2022)
  • Table 103. Middle East Cancer Photodynamic Therapy, by Application USD Million (2017-2022)
  • Table 104. Middle East Cancer Photodynamic Therapy, by End-users USD Million (2017-2022)
  • Table 105. Middle East Cancer Photodynamic Therapy, by Side Effects USD Million (2017-2022)
  • Table 106. Africa Cancer Photodynamic Therapy, by Type USD Million (2017-2022)
  • Table 107. Africa Cancer Photodynamic Therapy, by Application USD Million (2017-2022)
  • Table 108. Africa Cancer Photodynamic Therapy, by End-users USD Million (2017-2022)
  • Table 109. Africa Cancer Photodynamic Therapy, by Side Effects USD Million (2017-2022)
  • Table 110. North America Cancer Photodynamic Therapy, by Country USD Million (2017-2022)
  • Table 111. North America Cancer Photodynamic Therapy, by Type USD Million (2017-2022)
  • Table 112. North America Cancer Photodynamic Therapy, by Application USD Million (2017-2022)
  • Table 113. North America Cancer Photodynamic Therapy, by End-users USD Million (2017-2022)
  • Table 114. North America Cancer Photodynamic Therapy, by Side Effects USD Million (2017-2022)
  • Table 115. United States Cancer Photodynamic Therapy, by Type USD Million (2017-2022)
  • Table 116. United States Cancer Photodynamic Therapy, by Application USD Million (2017-2022)
  • Table 117. United States Cancer Photodynamic Therapy, by End-users USD Million (2017-2022)
  • Table 118. United States Cancer Photodynamic Therapy, by Side Effects USD Million (2017-2022)
  • Table 119. Canada Cancer Photodynamic Therapy, by Type USD Million (2017-2022)
  • Table 120. Canada Cancer Photodynamic Therapy, by Application USD Million (2017-2022)
  • Table 121. Canada Cancer Photodynamic Therapy, by End-users USD Million (2017-2022)
  • Table 122. Canada Cancer Photodynamic Therapy, by Side Effects USD Million (2017-2022)
  • Table 123. Mexico Cancer Photodynamic Therapy, by Type USD Million (2017-2022)
  • Table 124. Mexico Cancer Photodynamic Therapy, by Application USD Million (2017-2022)
  • Table 125. Mexico Cancer Photodynamic Therapy, by End-users USD Million (2017-2022)
  • Table 126. Mexico Cancer Photodynamic Therapy, by Side Effects USD Million (2017-2022)
  • Table 127. Company Basic Information, Sales Area and Its Competitors
  • Table 128. Company Basic Information, Sales Area and Its Competitors
  • Table 129. Company Basic Information, Sales Area and Its Competitors
  • Table 130. Company Basic Information, Sales Area and Its Competitors
  • Table 131. Company Basic Information, Sales Area and Its Competitors
  • Table 132. Company Basic Information, Sales Area and Its Competitors
  • Table 133. Company Basic Information, Sales Area and Its Competitors
  • Table 134. Company Basic Information, Sales Area and Its Competitors
  • Table 135. Company Basic Information, Sales Area and Its Competitors
  • Table 136. Company Basic Information, Sales Area and Its Competitors
  • Table 137. Cancer Photodynamic Therapy: by Type(USD Million)
  • Table 138. Cancer Photodynamic Therapy Drugs , by Region USD Million (2023-2028)
  • Table 139. Cancer Photodynamic Therapy Devices , by Region USD Million (2023-2028)
  • Table 140. Cancer Photodynamic Therapy: by Application(USD Million)
  • Table 141. Cancer Photodynamic Therapy Actinic Keratosis (AK) , by Region USD Million (2023-2028)
  • Table 142. Cancer Photodynamic Therapy Cancer , by Region USD Million (2023-2028)
  • Table 143. Cancer Photodynamic Therapy Acne , by Region USD Million (2023-2028)
  • Table 144. Cancer Photodynamic Therapy Psoriasis , by Region USD Million (2023-2028)
  • Table 145. Cancer Photodynamic Therapy Others , by Region USD Million (2023-2028)
  • Table 146. Cancer Photodynamic Therapy: by End-users(USD Million)
  • Table 147. Cancer Photodynamic Therapy Hospitals , by Region USD Million (2023-2028)
  • Table 148. Cancer Photodynamic Therapy Cancer Treatment Centers , by Region USD Million (2023-2028)
  • Table 149. Cancer Photodynamic Therapy Cosmetic and Dermatology Clinics , by Region USD Million (2023-2028)
  • Table 150. Cancer Photodynamic Therapy Others , by Region USD Million (2023-2028)
  • Table 151. Cancer Photodynamic Therapy: by Side Effects(USD Million)
  • Table 152. Cancer Photodynamic Therapy Cough , by Region USD Million (2023-2028)
  • Table 153. Cancer Photodynamic Therapy Trouble Swallowing , by Region USD Million (2023-2028)
  • Table 154. Cancer Photodynamic Therapy Stomach Pain , by Region USD Million (2023-2028)
  • Table 155. Cancer Photodynamic Therapy Painful Breathing , by Region USD Million (2023-2028)
  • Table 156. Cancer Photodynamic Therapy Shortness of Breath , by Region USD Million (2023-2028)
  • Table 157. Cancer Photodynamic Therapy Skin Problems , by Region USD Million (2023-2028)
  • Table 158. South America Cancer Photodynamic Therapy, by Country USD Million (2023-2028)
  • Table 159. South America Cancer Photodynamic Therapy, by Type USD Million (2023-2028)
  • Table 160. South America Cancer Photodynamic Therapy, by Application USD Million (2023-2028)
  • Table 161. South America Cancer Photodynamic Therapy, by End-users USD Million (2023-2028)
  • Table 162. South America Cancer Photodynamic Therapy, by Side Effects USD Million (2023-2028)
  • Table 163. Brazil Cancer Photodynamic Therapy, by Type USD Million (2023-2028)
  • Table 164. Brazil Cancer Photodynamic Therapy, by Application USD Million (2023-2028)
  • Table 165. Brazil Cancer Photodynamic Therapy, by End-users USD Million (2023-2028)
  • Table 166. Brazil Cancer Photodynamic Therapy, by Side Effects USD Million (2023-2028)
  • Table 167. Argentina Cancer Photodynamic Therapy, by Type USD Million (2023-2028)
  • Table 168. Argentina Cancer Photodynamic Therapy, by Application USD Million (2023-2028)
  • Table 169. Argentina Cancer Photodynamic Therapy, by End-users USD Million (2023-2028)
  • Table 170. Argentina Cancer Photodynamic Therapy, by Side Effects USD Million (2023-2028)
  • Table 171. Rest of South America Cancer Photodynamic Therapy, by Type USD Million (2023-2028)
  • Table 172. Rest of South America Cancer Photodynamic Therapy, by Application USD Million (2023-2028)
  • Table 173. Rest of South America Cancer Photodynamic Therapy, by End-users USD Million (2023-2028)
  • Table 174. Rest of South America Cancer Photodynamic Therapy, by Side Effects USD Million (2023-2028)
  • Table 175. Asia Pacific Cancer Photodynamic Therapy, by Country USD Million (2023-2028)
  • Table 176. Asia Pacific Cancer Photodynamic Therapy, by Type USD Million (2023-2028)
  • Table 177. Asia Pacific Cancer Photodynamic Therapy, by Application USD Million (2023-2028)
  • Table 178. Asia Pacific Cancer Photodynamic Therapy, by End-users USD Million (2023-2028)
  • Table 179. Asia Pacific Cancer Photodynamic Therapy, by Side Effects USD Million (2023-2028)
  • Table 180. China Cancer Photodynamic Therapy, by Type USD Million (2023-2028)
  • Table 181. China Cancer Photodynamic Therapy, by Application USD Million (2023-2028)
  • Table 182. China Cancer Photodynamic Therapy, by End-users USD Million (2023-2028)
  • Table 183. China Cancer Photodynamic Therapy, by Side Effects USD Million (2023-2028)
  • Table 184. Japan Cancer Photodynamic Therapy, by Type USD Million (2023-2028)
  • Table 185. Japan Cancer Photodynamic Therapy, by Application USD Million (2023-2028)
  • Table 186. Japan Cancer Photodynamic Therapy, by End-users USD Million (2023-2028)
  • Table 187. Japan Cancer Photodynamic Therapy, by Side Effects USD Million (2023-2028)
  • Table 188. India Cancer Photodynamic Therapy, by Type USD Million (2023-2028)
  • Table 189. India Cancer Photodynamic Therapy, by Application USD Million (2023-2028)
  • Table 190. India Cancer Photodynamic Therapy, by End-users USD Million (2023-2028)
  • Table 191. India Cancer Photodynamic Therapy, by Side Effects USD Million (2023-2028)
  • Table 192. South Korea Cancer Photodynamic Therapy, by Type USD Million (2023-2028)
  • Table 193. South Korea Cancer Photodynamic Therapy, by Application USD Million (2023-2028)
  • Table 194. South Korea Cancer Photodynamic Therapy, by End-users USD Million (2023-2028)
  • Table 195. South Korea Cancer Photodynamic Therapy, by Side Effects USD Million (2023-2028)
  • Table 196. Australia Cancer Photodynamic Therapy, by Type USD Million (2023-2028)
  • Table 197. Australia Cancer Photodynamic Therapy, by Application USD Million (2023-2028)
  • Table 198. Australia Cancer Photodynamic Therapy, by End-users USD Million (2023-2028)
  • Table 199. Australia Cancer Photodynamic Therapy, by Side Effects USD Million (2023-2028)
  • Table 200. Rest of Asia-Pacific Cancer Photodynamic Therapy, by Type USD Million (2023-2028)
  • Table 201. Rest of Asia-Pacific Cancer Photodynamic Therapy, by Application USD Million (2023-2028)
  • Table 202. Rest of Asia-Pacific Cancer Photodynamic Therapy, by End-users USD Million (2023-2028)
  • Table 203. Rest of Asia-Pacific Cancer Photodynamic Therapy, by Side Effects USD Million (2023-2028)
  • Table 204. Europe Cancer Photodynamic Therapy, by Country USD Million (2023-2028)
  • Table 205. Europe Cancer Photodynamic Therapy, by Type USD Million (2023-2028)
  • Table 206. Europe Cancer Photodynamic Therapy, by Application USD Million (2023-2028)
  • Table 207. Europe Cancer Photodynamic Therapy, by End-users USD Million (2023-2028)
  • Table 208. Europe Cancer Photodynamic Therapy, by Side Effects USD Million (2023-2028)
  • Table 209. Germany Cancer Photodynamic Therapy, by Type USD Million (2023-2028)
  • Table 210. Germany Cancer Photodynamic Therapy, by Application USD Million (2023-2028)
  • Table 211. Germany Cancer Photodynamic Therapy, by End-users USD Million (2023-2028)
  • Table 212. Germany Cancer Photodynamic Therapy, by Side Effects USD Million (2023-2028)
  • Table 213. France Cancer Photodynamic Therapy, by Type USD Million (2023-2028)
  • Table 214. France Cancer Photodynamic Therapy, by Application USD Million (2023-2028)
  • Table 215. France Cancer Photodynamic Therapy, by End-users USD Million (2023-2028)
  • Table 216. France Cancer Photodynamic Therapy, by Side Effects USD Million (2023-2028)
  • Table 217. Italy Cancer Photodynamic Therapy, by Type USD Million (2023-2028)
  • Table 218. Italy Cancer Photodynamic Therapy, by Application USD Million (2023-2028)
  • Table 219. Italy Cancer Photodynamic Therapy, by End-users USD Million (2023-2028)
  • Table 220. Italy Cancer Photodynamic Therapy, by Side Effects USD Million (2023-2028)
  • Table 221. United Kingdom Cancer Photodynamic Therapy, by Type USD Million (2023-2028)
  • Table 222. United Kingdom Cancer Photodynamic Therapy, by Application USD Million (2023-2028)
  • Table 223. United Kingdom Cancer Photodynamic Therapy, by End-users USD Million (2023-2028)
  • Table 224. United Kingdom Cancer Photodynamic Therapy, by Side Effects USD Million (2023-2028)
  • Table 225. Netherlands Cancer Photodynamic Therapy, by Type USD Million (2023-2028)
  • Table 226. Netherlands Cancer Photodynamic Therapy, by Application USD Million (2023-2028)
  • Table 227. Netherlands Cancer Photodynamic Therapy, by End-users USD Million (2023-2028)
  • Table 228. Netherlands Cancer Photodynamic Therapy, by Side Effects USD Million (2023-2028)
  • Table 229. Rest of Europe Cancer Photodynamic Therapy, by Type USD Million (2023-2028)
  • Table 230. Rest of Europe Cancer Photodynamic Therapy, by Application USD Million (2023-2028)
  • Table 231. Rest of Europe Cancer Photodynamic Therapy, by End-users USD Million (2023-2028)
  • Table 232. Rest of Europe Cancer Photodynamic Therapy, by Side Effects USD Million (2023-2028)
  • Table 233. MEA Cancer Photodynamic Therapy, by Country USD Million (2023-2028)
  • Table 234. MEA Cancer Photodynamic Therapy, by Type USD Million (2023-2028)
  • Table 235. MEA Cancer Photodynamic Therapy, by Application USD Million (2023-2028)
  • Table 236. MEA Cancer Photodynamic Therapy, by End-users USD Million (2023-2028)
  • Table 237. MEA Cancer Photodynamic Therapy, by Side Effects USD Million (2023-2028)
  • Table 238. Middle East Cancer Photodynamic Therapy, by Type USD Million (2023-2028)
  • Table 239. Middle East Cancer Photodynamic Therapy, by Application USD Million (2023-2028)
  • Table 240. Middle East Cancer Photodynamic Therapy, by End-users USD Million (2023-2028)
  • Table 241. Middle East Cancer Photodynamic Therapy, by Side Effects USD Million (2023-2028)
  • Table 242. Africa Cancer Photodynamic Therapy, by Type USD Million (2023-2028)
  • Table 243. Africa Cancer Photodynamic Therapy, by Application USD Million (2023-2028)
  • Table 244. Africa Cancer Photodynamic Therapy, by End-users USD Million (2023-2028)
  • Table 245. Africa Cancer Photodynamic Therapy, by Side Effects USD Million (2023-2028)
  • Table 246. North America Cancer Photodynamic Therapy, by Country USD Million (2023-2028)
  • Table 247. North America Cancer Photodynamic Therapy, by Type USD Million (2023-2028)
  • Table 248. North America Cancer Photodynamic Therapy, by Application USD Million (2023-2028)
  • Table 249. North America Cancer Photodynamic Therapy, by End-users USD Million (2023-2028)
  • Table 250. North America Cancer Photodynamic Therapy, by Side Effects USD Million (2023-2028)
  • Table 251. United States Cancer Photodynamic Therapy, by Type USD Million (2023-2028)
  • Table 252. United States Cancer Photodynamic Therapy, by Application USD Million (2023-2028)
  • Table 253. United States Cancer Photodynamic Therapy, by End-users USD Million (2023-2028)
  • Table 254. United States Cancer Photodynamic Therapy, by Side Effects USD Million (2023-2028)
  • Table 255. Canada Cancer Photodynamic Therapy, by Type USD Million (2023-2028)
  • Table 256. Canada Cancer Photodynamic Therapy, by Application USD Million (2023-2028)
  • Table 257. Canada Cancer Photodynamic Therapy, by End-users USD Million (2023-2028)
  • Table 258. Canada Cancer Photodynamic Therapy, by Side Effects USD Million (2023-2028)
  • Table 259. Mexico Cancer Photodynamic Therapy, by Type USD Million (2023-2028)
  • Table 260. Mexico Cancer Photodynamic Therapy, by Application USD Million (2023-2028)
  • Table 261. Mexico Cancer Photodynamic Therapy, by End-users USD Million (2023-2028)
  • Table 262. Mexico Cancer Photodynamic Therapy, by Side Effects USD Million (2023-2028)
  • Table 263. Research Programs/Design for This Report
  • Table 264. Key Data Information from Secondary Sources
  • Table 265. Key Data Information from Primary Sources
List of Figures
  • Figure 1. Porters Five Forces
  • Figure 2. Supply/Value Chain
  • Figure 3. PESTEL analysis
  • Figure 4. Global Cancer Photodynamic Therapy: by Type USD Million (2017-2022)
  • Figure 5. Global Cancer Photodynamic Therapy: by Application USD Million (2017-2022)
  • Figure 6. Global Cancer Photodynamic Therapy: by End-users USD Million (2017-2022)
  • Figure 7. Global Cancer Photodynamic Therapy: by Side Effects USD Million (2017-2022)
  • Figure 8. South America Cancer Photodynamic Therapy Share (%), by Country
  • Figure 9. Asia Pacific Cancer Photodynamic Therapy Share (%), by Country
  • Figure 10. Europe Cancer Photodynamic Therapy Share (%), by Country
  • Figure 11. MEA Cancer Photodynamic Therapy Share (%), by Country
  • Figure 12. North America Cancer Photodynamic Therapy Share (%), by Country
  • Figure 13. Global Cancer Photodynamic Therapy share by Players 2022 (%)
  • Figure 14. Global Cancer Photodynamic Therapy share by Players (Top 3) 2022(%)
  • Figure 15. Global Cancer Photodynamic Therapy share by Players (Top 5) 2022(%)
  • Figure 16. BCG Matrix for key Companies
  • Figure 17. Theralase Technologies Inc. (Canada) Revenue, Net Income and Gross profit
  • Figure 18. Theralase Technologies Inc. (Canada) Revenue: by Geography 2022
  • Figure 19. Biofrontera AG (Germany) Revenue, Net Income and Gross profit
  • Figure 20. Biofrontera AG (Germany) Revenue: by Geography 2022
  • Figure 21. Hologic Inc. (United States) Revenue, Net Income and Gross profit
  • Figure 22. Hologic Inc. (United States) Revenue: by Geography 2022
  • Figure 23. Bausch Health (Canada) Revenue, Net Income and Gross profit
  • Figure 24. Bausch Health (Canada) Revenue: by Geography 2022
  • Figure 25. Quest PharmaTech Inc. (Canada) Revenue, Net Income and Gross profit
  • Figure 26. Quest PharmaTech Inc. (Canada) Revenue: by Geography 2022
  • Figure 27. LUMIBIRD (France) Revenue, Net Income and Gross profit
  • Figure 28. LUMIBIRD (France) Revenue: by Geography 2022
  • Figure 29. Galderma Laboratories L.P. (Switzerland) Revenue, Net Income and Gross profit
  • Figure 30. Galderma Laboratories L.P. (Switzerland) Revenue: by Geography 2022
  • Figure 31. Sun Pharmaceutical Industries Limited (India) Revenue, Net Income and Gross profit
  • Figure 32. Sun Pharmaceutical Industries Limited (India) Revenue: by Geography 2022
  • Figure 33. Allergan plc (Ireland) Revenue, Net Income and Gross profit
  • Figure 34. Allergan plc (Ireland) Revenue: by Geography 2022
  • Figure 35. Modulight Inc. (Finland) Revenue, Net Income and Gross profit
  • Figure 36. Modulight Inc. (Finland) Revenue: by Geography 2022
  • Figure 37. Global Cancer Photodynamic Therapy: by Type USD Million (2023-2028)
  • Figure 38. Global Cancer Photodynamic Therapy: by Application USD Million (2023-2028)
  • Figure 39. Global Cancer Photodynamic Therapy: by End-users USD Million (2023-2028)
  • Figure 40. Global Cancer Photodynamic Therapy: by Side Effects USD Million (2023-2028)
  • Figure 41. South America Cancer Photodynamic Therapy Share (%), by Country
  • Figure 42. Asia Pacific Cancer Photodynamic Therapy Share (%), by Country
  • Figure 43. Europe Cancer Photodynamic Therapy Share (%), by Country
  • Figure 44. MEA Cancer Photodynamic Therapy Share (%), by Country
  • Figure 45. North America Cancer Photodynamic Therapy Share (%), by Country
List of companies from research coverage that are profiled in the study
  • Theralase Technologies Inc. (Canada)
  • Biofrontera AG (Germany)
  • Hologic Inc. (United States)
  • Bausch Health (Canada)
  • Quest PharmaTech Inc. (Canada)
  • LUMIBIRD (France)
  • Galderma Laboratories L.P. (Switzerland)
  • Sun Pharmaceutical Industries Limited (India)
  • Allergan plc (Ireland)
  • Modulight Inc. (Finland)
Additional players considered in the study are as follows:
SUS Advancing Technology Co. Ltd (China) , Lumenis Ltd. (Israel) , PhotoMedex Inc. (United States) , Dusa Pharmaceuticals (United States) , Soligenix Inc. (United States)
Select User Access Type

Key Highlights of Report


May 2023 208 Pages 68 Tables Base Year: 2022 Coverage: 15+ Companies; 18 Countries

Request Sample Pages

Budget constraints? Get in touch with us for special pricing


Check Discount Now

Talk to Our Experts

Want to Customize Study?


"We employ Market statistics, Industry benchmarking, Patent analysis, and Technological Insights to derive requirements and provide customize scope of work."

Make an Enquiry Now

Frequently Asked Questions (FAQ):

Top performing companies in the Global Cancer Photodynamic Therapy market are Theralase Technologies Inc. (Canada), Biofrontera AG (Germany), Hologic Inc. (United States), Bausch Health (Canada), Quest PharmaTech Inc. (Canada), LUMIBIRD (France), Galderma Laboratories L.P. (Switzerland), Sun Pharmaceutical Industries Limited (India), Allergan plc (Ireland) and Modulight Inc. (Finland), to name a few.
"Developing Improved Formulations of Porphyrin-Derivative (PD) Compounds" is seen as one of major influencing trends for Cancer Photodynamic Therapy Market during projected period 2022-2028.
Drugs segment in Global market to hold robust market share owing to "Increasing Prevalence of Skin Cancer ".

Know More About Global Cancer Photodynamic Therapy Market Report?